Fitusiran (ALN-AT3SC)
Revision as of 21:53, 28 October 2023 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== siRNA therapeutic, targets antithrombin ==Preliminary data== ===Inherited coagulopathy=== #'''ATLAS-A/B:''' Srivastava A, Rangarajan S, Kavakli K,...")
Mechanism of action
siRNA therapeutic, targets antithrombin
Preliminary data
Inherited coagulopathy
- ATLAS-A/B: Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, You CW, Xu W, Malan N, Frenzel L, Bagot CN, Stasyshyn O, Chang CY, Poloskey S, Qiu Z, Andersson S, Mei B, Pipe SW. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023 May;10(5):e322-e332. Epub 2023 Mar 29. link to original article PubMed NCT03417245